Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

The use of radioimmunoconjugates in stem cell transplantation

Bone Marrow Transplantation volume 29, pages 807–816 (2002)Cite this article

Abstract

Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 and CD22 for non-Hodgkin's lymphomas, and ferritin for Hodgkin's disease. The results obtained targeting epithelial antigens on solid tumors, however, have generally been less encouraging, primarily due to the relative insensitivity of these malignancies to ionizing radiation. In this report we review clinical studies that have incorporated myeloablative doses of targeted radiation using radiolabeled antibodies in conjunction with stem cell transplant regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Press OW, Rasey J . Principles of radioimmunotherapy for hematologists and oncologists Semin Oncol 2000 27: 62 73

    CAS  PubMed  Google Scholar 

  2. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New Engl J Med 1991 325: 1525 33

    Article  CAS  PubMed  Google Scholar 

  3. Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H Br J Haematol 1997 97: 669 672

    Article  CAS  PubMed  Google Scholar 

  4. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864 869

    CAS  PubMed  Google Scholar 

  5. Horwitz SM, Breslin S, Negrin RS et al. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma (NHL): preliminary results of a phase I–II trial Proc Am Soc Clin Oncol 2000 19: 51a

    Google Scholar 

  6. Press OW . Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma Semin Hematol 2000 37: 2 8

    Article  CAS  PubMed  Google Scholar 

  7. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled antibody therapy of lymphomas. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer Updates V JB Lippincott Co: Philadelphia 1994 1 13

    Google Scholar 

  8. Press OW, Farr AG, Borroz KI et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies Cancer Res 1989 49: 4906 4912

    CAS  PubMed  Google Scholar 

  9. Press OW, Howell-Clark J, Anderson S et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells Blood 1994 83: 1390 1397

    CAS  PubMed  Google Scholar 

  10. Press OW, Shan D, Howell-Clark J et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells Cancer Res 1996 56: 2123 2129

    CAS  PubMed  Google Scholar 

  11. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 1990 76: 1867 1871

    CAS  PubMed  Google Scholar 

  12. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens Blood 1991 77: 1660 1665

    CAS  PubMed  Google Scholar 

  13. Andrews RG, Takahashi M, Segal GM et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors Blood 1986 68: 1030 1035

    CAS  PubMed  Google Scholar 

  14. Griffin JD, Linch D, Sabbath K et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk Res 1984 8: 521 534

    Article  CAS  PubMed  Google Scholar 

  15. Dinndorf PA, Andrews RG, Benjamin D et al. Expression of normal myeloid-associated antigens by acute leukemia cells Blood 1986 67: 1048 1053

    CAS  PubMed  Google Scholar 

  16. Caron PC, Dumont L, Scheinberg DA . Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia Clin Cancer Res 1998 4: 1421 1428

    CAS  PubMed  Google Scholar 

  17. Feldman E, Kalaycio M, Schulman P et al. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a phase II study Proc Am Soc Clin Oncol 1999 18: 4a

    Google Scholar 

  18. Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia Transplantation 1992 54: 829 833

    Article  CAS  PubMed  Google Scholar 

  19. Jurcic JG, Caron PC, Nikula TK et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: 5908s 5910s

    CAS  PubMed  Google Scholar 

  20. Jurcic JG, Divgi CR, McDevitt MR et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia Proc Am Soc Clin Oncol 2000 19: 8a

    Google Scholar 

  21. Hinman LM, Hamann PR, Wallace R et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res 1993 53: 3336 3342

    CAS  PubMed  Google Scholar 

  22. Sievers EL, Appelbaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678 3684

    CAS  PubMed  Google Scholar 

  23. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 19: 3244 3254

    Article  CAS  PubMed  Google Scholar 

  24. Omary MB, Trowbridge IS, Battifora HA . Human homologue of murine T200 glycoprotein J Exp Med 1980 152: 842 852

    Article  CAS  PubMed  Google Scholar 

  25. Andres TL, Kadin ME . Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia Am J Clin Pathol 1983 79: 546 552

    Article  CAS  PubMed  Google Scholar 

  26. Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 1999 94: 1237 1247

    CAS  PubMed  Google Scholar 

  27. Matthews DC, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission Blood 1996 88: 142a

    Google Scholar 

  28. Ruffner KL, Matthews DC . Current uses of monoclonal antibodies in the treatment of acute leukemia Semin Oncol 2000 27: 531 539

    CAS  PubMed  Google Scholar 

  29. Blaise D, Maraninchi D, Michallet M et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission Blood 2001 97: 3669 3371

    Article  CAS  PubMed  Google Scholar 

  30. Becker W, Goldenberg D, Wolf F . The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions Semin Nucl Med 1994 25: 1 13

    Google Scholar 

  31. Noworolska A, Harlozinska A, Richter R et al. Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series Br J Cancer 1985 51: 371 377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Boccuni P, Di Noto R, Lo Pardo C et al. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies Tissue Antigens 1998 52: 1 8

    Article  CAS  PubMed  Google Scholar 

  33. Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study Blood 2001 98: 565 572

    Article  CAS  PubMed  Google Scholar 

  34. Juweid M, Sharkey RM, Markowitz A et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 1995 55: 5899s 5907s

    CAS  PubMed  Google Scholar 

  35. Juweid ME, Stadtmauer E, Hajjar G et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma Clin Cancer Res 1999 5: 3292s 3303s

    CAS  PubMed  Google Scholar 

  36. Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res 1996 2: 457 470

    CAS  PubMed  Google Scholar 

  37. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 2000 96: 1259 1266

    CAS  PubMed  Google Scholar 

  38. Kaminski M, Zelenetz A, Press O et al. Multicenter phase III study of Iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin's lymphoma Blood 1998 92: 316a (Abstr.)

    Google Scholar 

  39. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support (see comments) New Engl J Med 1993 329: 1219 1224

    Article  CAS  PubMed  Google Scholar 

  40. Press OW, Eary JF, Appelbaum FR et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 1995 346: 336 340

    Article  CAS  PubMed  Google Scholar 

  41. Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue J Clin Oncol 1998 16: 3270 3278

    Article  CAS  PubMed  Google Scholar 

  42. Press OW, Eary JF, Gooley T et al. A phase I/II trial of Iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas Blood 2001 96: 2934 2942

    Google Scholar 

  43. Vose JM, Bierman PJ, Lynch JC et al. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity Proc Am Soc Clin Oncol 2001 20: 6a

    Google Scholar 

  44. Lenhard RE Jr, Order SE, Spunberg JJ et al. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease J Clin Oncol 1985 3: 1296 1300

    Article  PubMed  Google Scholar 

  45. Vriesendorp HM, Herpst JM, Germack MA et al. Phase I–II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 J Clin Oncol 1991 9: 918 928

    Article  CAS  PubMed  Google Scholar 

  46. Herpst JM, Klein JL, Leichner PK et al. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment J Clin Oncol 1995 13: 2394 2400

    Article  CAS  PubMed  Google Scholar 

  47. Bierman PJ, Vose JM, Leichner PK et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease J Clin Oncol 1993 11: 698 703

    Article  CAS  PubMed  Google Scholar 

  48. Appelbaum FR, Brown PA, Sandmaier BM et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP Blood 1992 80: 1608 1613

    CAS  PubMed  Google Scholar 

  49. Giralt S, Champlin R, Goodman M et al. Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166Holmium-DOTMP in combination with high dose melphalan +/− total body irradiation (TBI) with autologous stem cell transplant Blood 2000 96: 558a

    Google Scholar 

  50. Giralt S, Bensinger W, Wendt R III et al. Hemorrhagic cystitis after targeted radiotherapy with 166Holmium-DOTMP (166HO) for multiple myeloma (MM) is preventable with bladder irrigation Blood 2000 96: 391a

    Google Scholar 

  51. Tempero M, Leichner P, Dalrymple G et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial J Clin Oncol 1997 15: 1518 1528

    Article  CAS  PubMed  Google Scholar 

  52. Colcher D, Minelli MF, Roselli M et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies Cancer Res 1988 48: 4597 4603

    CAS  PubMed  Google Scholar 

  53. Denardo SJ, O'Grady LF, Richman CM et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody Anticancer Res 1997 17: 1745 1751

    CAS  PubMed  Google Scholar 

  54. Richman CM, DeNardo SJ, O'Grady LF et al. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions Cancer Res 1995 55: 5916s 5920s

    CAS  PubMed  Google Scholar 

  55. Richman CM, DeNardo SJ, O'Grady LF et al. Fractionated intensive-dose radioimmunotherapy for breast cancer using I-131 chimeric (Ch) L6 with peripheral blood stem cell (PBSC) support and cyclosporin (CSA) Proc Am Soc Clin Oncol 1995 14: 322

    Google Scholar 

  56. Richman CM, DeNardo SJ . Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies Crit Rev Oncol Hematol 2001 38: 25 35

    Article  CAS  PubMed  Google Scholar 

  57. Juweid M, Neumann R, Paik C et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier Cancer Res 1992 52: 5144 5153

    CAS  PubMed  Google Scholar 

  58. Baxter LT, Jain RK . Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution Microvasc Res 1991 41: 252 272

    Article  CAS  PubMed  Google Scholar 

  59. Fujimori K, Covell DG, Fletcher JE et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J Nucl Med 1990 31: 1191 1198

    CAS  PubMed  Google Scholar 

  60. Yokota T, Milenic DE, Whitlow M et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 1992 52: 3402 3408

    CAS  PubMed  Google Scholar 

  61. Hu S, Shively L, Raubitschek A et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts Cancer Res 1996 56: 3055 3061

    CAS  PubMed  Google Scholar 

  62. King DJ, Turner A, Farnsworth AP et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments Cancer Res 1994 54: 6176 6185

    CAS  PubMed  Google Scholar 

  63. Jurcic JG, McDevitt MR, Sgouros G et al. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (Anti-CD33) Proc Am Soc Clin Oncol 1999 18: 7a

    Google Scholar 

  64. Sgouros G, Ballangrud AM, Jurcic JG et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia J Nucl Med 1999 40: 1935 1946

    CAS  PubMed  Google Scholar 

  65. McDevitt MR, Ma D, Lai LT et al. Tumor therapy with targeted atomic nanogenerators Science 2001 294: 1537 1540

    Article  CAS  PubMed  Google Scholar 

  66. McDevitt MR, Sgouros G, Finn RD et al. Radioimmunotherapy with alpha-emitting nuclides Eur J Nucl Med 1998 25: 1341 1351

    Article  CAS  PubMed  Google Scholar 

  67. Axworthy DB, Reno JM, Hylarides MD et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity Proc Natl Acad Sci USA 2000 97: 1802 1807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Press OW, Corcoran M, Subbiah K et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts Blood 2001 98: 2535 2543

    Article  CAS  PubMed  Google Scholar 

  69. Weiden PL, Breitz HB, Press O et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results Cancer Biother Radiopharm 2000 15: 15 29

    Article  CAS  PubMed  Google Scholar 

  70. Hall EJ . Cellular effects of ionizing radiation. In: Tubiana M, Dutreix J, Wambersie A (eds) Introduction to Radiobiology Taylor & Francis: London, UK 1990 86 125

    Google Scholar 

  71. Winter JN, Inwards D, Erwin W et al. Phase I trial combining 90Y zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL Blood 2001 98: 677a

    Google Scholar 

  72. Schrier DM, Stemmer SM, Johnson T et al. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial Cancer Res 1995 55: 5921s 5924s

    CAS  PubMed  Google Scholar 

  73. Cagnoni PJ, Ceriani RL, Cole WC et al. Phase I study of high-dose radioimmunotherapy 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer Cancer Biother Radiopharma 1998 13: 328 (Abstr.)

    Google Scholar 

  74. Wong JYC, Somlo G, Odom-Maryon T et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 (cT84.66) anti-carcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with anti-carcinoembryonic antigen-producing metastatic breast cancer Clin Cancer Res 1999 5: 3224s 3231s

    CAS  PubMed  Google Scholar 

  75. Richman CM, DeNardo SJ, O'Donnell RT et al. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A Clin Cancer Res 1999 5: 3243s 3248s

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    JM Pagel, DC Matthews, FR Appelbaum, ID Bernstein & OW Press

  2. Department of Medicine, University of Washington, Seattle, WA, USA

    JM Pagel, FR Appelbaum & OW Press

  3. Department of Pediatrics, University of Washington, Seattle, WA, USA

    DC Matthews & ID Bernstein

  4. Department of Biological Structure, University of Washington, Seattle, WA, USA

    OW Press

Authors
  1. JM Pagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. DC Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. FR Appelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. ID Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. OW Press
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pagel, J., Matthews, D., Appelbaum, F. et al. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 29, 807–816 (2002). https://doi.org/10.1038/sj.bmt.1703524

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703524

Keywords

This article is cited by

Search

Advanced search

Quick links